MediView XR, a medical technology (medtech) company specialising in augmented reality (AR), has recently announced that its AR surgical navigation system, XR90, has received FDA 510(k) clearance.
The XR90 platform provides augmented reality visualisation and surgical navigation capabilities, enabling healthcare providers to view 3D representations of a patient's internal soft tissues, vascular, organ, and skeletal structures based on CT images.
The system combines CT imaging with ultrasound technology, allowing 3D holographic images to be displayed anatomically beneath the patient's skin. This innovative feature empowers healthcare professionals to conduct minimally invasive procedures, such as tumour ablations and biopsies. For surgical navigation, the platform utilises a Holographic Light Ray to track and display the path of a physician's instrument.
In March, MediView XR secured $15 million in strategic funding, building on its earlier $9.9 million investment. In December, the company entered into a know-how agreement with Mayo Clinic, benefiting from the health system's technology, clinical, and research expertise to accelerate innovation in procedural augmented reality solutions.
Moreover, MediView XR teamed up with GE Healthcare to co-develop the OmnifyXR Interventional Suite System, combining GE's imaging technologies with MediView's augmented reality and surgical navigation expertise. The collaborative effort aims to enable physicians to evaluate multiple holographic displays of live imaging in 3D.
Several other companies in the industry are also offering surgical navigation platforms that utilise extended reality technology. For instance, Augmedics recently raised $82.5 million in Series D financing, and Osso VR secured $66 million in Series C funding in 2022 and $27 million in Series B funding in 2021. The growing interest and investment in this field signify the potential transformative impact of AR technology on surgical procedures and medical interventions.
Click here to read the original news story.